BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s iohexol injection (300 ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's ...
Hosted on MSN
Amneal gets FDA nod for Iohexol Injection
Amneal Pharmaceuticals (AMRX) has received approval from the U.S. FDA for its iohexol injection, which contains 300 mg of iodine per mL. This marks the introduction of the first generic version of GE ...
Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque, with plans to launch in the first ...
Iohexol is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular and body cavity imaging procedures. “We are very proud to introduce the ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Thursday that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic ...
AJR: resources required to warm iohexol 350 to body temperature before injection for CT may not be warranted, given lack of observed practical benefit “The data suggest that maintaining iohexol 350 at ...
(MENAFN- GlobeNewsWire - Nasdaq) First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results